Sacubitril/Valsartan can improve the cardiac function in heart failure patients with a history of cancer: A real-world retrospective study about aged population

Abstract Amis Sacubitril/Valsartan is now becoming the class one recommendation for HFrEF. Some studies have shown the positive effect of Sacubitril/Valsartan on HFrEF cancer patients, while there is devoid of evidence about the effect of this drug in aged cancer patients with HFmrEF and HFpEF. We did this retrospective study to investigate the beneficial effect of Sacubitril/Valsartan on all three kinds of HF patients with cancer in the aged population. Method and results By searching the patients with a diagnosis of both cancer and heart failure over 65, the patients who had received treatment with Sacubitril/Valsartan were selected as the candidates for Sacubitril/Valsartan group, and the patients who had received conventional HF therapy without Sacubitril/Valsartan were chosen as the control group. Data were collected for up to 9 months. We filtered 38 patients and 50 patients valid for Sacubitril/Valsartan group and control group, respectively. After initiation of heart failure management, our study found a better cardiac condition in Sacubitril/Valsartan group, having better LVEF, LVFS, NT-proBNP in 3rd, 6th, 9th month (P<0.05) and better NYHA function classification after the treatment. We also observed fewer cases of deterioration on LAD (p=0.029) and LVEDD (p=0.023) in Sacubitril/Valsartan group. In subgroup analysis, our study showed that all three kinds of HF patients had better LVEF, LVFS, and NT-proBNP in Sacubitril/Valsartan group (P<0.05). Conclusion Our study further indicated that Sacubitril/Valsartan can improve cardiac function and benefit cardiac remolding in aged cancer patients of all three kinds of HF. As we know, this is the first study to provide new evidence for the use of Sacubitril/Valsartan in aged cancer patients of all three kinds of HF.